Video

Gastrointestinal Stromal Tumor Diagnosis

The clinical presentation that is typically observed with gastrointestinal stromal tumors (GISTs) is somewhat nonspecific, states Anthony P. Conley, MD. Patients may report symptoms related to anemia, such as fatigue and changes in skin color, usually in the chronic setting. GISTs can be detected through upper endoscopy or colonoscopy, notes Conley, but may escape detection because they tend to arise in the muscular layer rather than the epithelial portion of the gastrointestinal tract. Once GIST is suspected, it is important to conduct a biopsy to rule out other diseases, such as leiomyomas and leiomyosarcomas, comments Conley.

The majority of patients with GIST are asymptomatic, says Robert H. I. Andtbacka, MD, although they may present with abdominal discomfort and gastrointestinal bleeding. A GIST diagnosis is often discovered with CT scan of the abdomen, pelvis, and small bowel, explains Andtbacka. Colonoscopies also help confirm that the malignancy is not adenocarcinoma, which is more common in these locations than GIST, says Andtbacka.

Obtaining a core biopsy also allows for immunohistochemical staining for mast/stem cell growth factor receptor, also known as c-KIT (CD117), platelet derived growth factor receptor, and other receptors. Staining positive for these markers can also indicate a GIST diagnosis, as approximately 95% of GIST tumors express c-KIT.

Related Videos
Brendon M. Stiles, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy in early-stage non–small cell lung cancer.
Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.
Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.
Samuel Cytryn, MD, and David B. Zhen, MD, on long-term data for nivolumab plus chemotherapy or ipilimumab in advanced esophageal squamous cell carcinoma.
Samuel Cytryn, MD, and David B. Zhen, MD, discuss findings from a Q-TWiST analysis of the CheckMate 649 trial in advanced gastric/GEJ cancer.
Samuel Cytryn, MD, and David B. Zhen, MD, on 4-year data from CheckMate 649 for nivolumab plus chemotherapy in first-line advanced gastric/GEJ cancer.
Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy has affected the treatment paradigm for upper gastrointestinal cancers.
Mary Philip, MD, PhD
Rom S. Leidner, MD
Sarwish Rafiq, PhD